Announcements


Date: 15 September 2017

OTHERS ASIA BIOENERGY TECHNOLOGIES BERHAD ("ABT" or "the Company") - SUBSCRIPTION OF RIGHTS AND EXCESS SHARES OF MLABS SYSTEMS BERHAD ("MLABS") PURSUANT TO RULE 9.19(26) AND RULE 10.06 OF THE ACE MARKET LISTING REQUIREMENTS


Type Announcement
Subject OTHERS
Description ASIA BIOENERGY TECHNOLOGIES BERHAD ("ABT" or "the Company") - SUBSCRIPTION OF RIGHTS AND EXCESS SHARES OF MLABS SYSTEMS BERHAD ("MLABS") PURSUANT TO RULE 9.19(26) AND RULE 10.06 OF THE ACE MARKET LISTING REQUIREMENTS

The Board of Directors of Asia Bioenergy Technologies Berhad ("ABT" or "the Company") wishes to announce that its wholly-owned subsidiary, Asiabio Capital Sdn. Bhd. has on 15 September 2017 acquired 75,100,000 shares of Mlabs Systems Berhad ("MLABS"), representing 13.16% equity interest in MLABS, via the subscription of the rights and excess shares of MLABS at an issue price of RM0.15 each ("Shares") for a total cash consideration of RM11,265,000 ("Consideration"). Pursuant to the acquisition, Asiabio Capital Sdn. Bhd. will also be issued 37,550,000 free Warrants B of MLABS.

 

Please refer to the attachment below for more details.



 


ATTACHMENT

- ABT - Chapter 9.19(26) (Subscription of Right and Excess Shares of Mlabs)(Final) - 15.09.2017.pdf

Back